Prescription Thyroid Medication TIROSINT Recalled for Subpotent Dosages Nationwide
IBSA Pharma is recalling certain lots of TIROSINT (levothyroxine sodium) oral solution nationwide because the product contains less active ingredient than labeled. Patients using affected lots may not receive adequate thyroid hormone replacement.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: While no illnesses or hospitalizations were reported, a subpotent thyroid medication represents a risk-of-harm situation because patients may not receive adequate hormone replacement therapy needed to manage their condition. This meets the rubric criterion for High severity: risk-of-harm products where injury has not yet been reported.
Plain-English summary
IBSA Pharma Inc. is recalling specific lots of TIROSINT (levothyroxine sodium) oral solution, a prescription thyroid medication. The product is supplied as an oral solution at 25 microgram/mL in packages of 6 pouches containing 5 ampules each. The affected lot is Lot #220856 with an expiration date of February 2024.
The recall was initiated because the medication is subpotent—it contains less levothyroxine sodium than the labeled amount. This means patients taking the affected product may not receive the full therapeutic dose needed to properly manage their thyroid condition.
The product was distributed nationwide in the United States. The recall is voluntary and was initiated by the firm on January 30, 2023, with FDA classification as a Class II recall. The recall was terminated on October 31, 2023.
Patients who have been prescribed TIROSINT from the affected lot should contact their healthcare provider or pharmacy to discuss whether their medication is from the recalled lot and to determine if their prescription needs to be replaced. Do not stop taking thyroid medication without consulting a healthcare provider, as abrupt discontinuation can be harmful.
The recalled product
- Product
- TIROSINT (LEVOTHYROXINE SODIUM)
- Brand
- TIROSINT
- Manufacturer
- IBSA PHARMA INC
- Hazard
- subpotent-drug
- underdose
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 220856
- Exp. 2/2024.
UPCs (15)
- 0371858011754
- 0371858013055
- 0371858012553
- 0371858011556
- 0371858015554
- 0371858013550
- 0371858015059
- 0371858014052
- 0371858016056
- 0371858014557
- 0371858010559
- 0371858011358
- 0371858011259
- 0371858011051
- 0371858012058
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TIROSINT
- HighLevothyroxine sodium oral solution recalled nationwide for subpotent dosing
FDA (Drugs) · 2023-03-01
- HighLevothyroxine Oral Solution TIROSINT Recalled Due to Subpotency
FDA (Drugs) · 2023-03-01
- ModerateTIROSINT Levothyroxine Oral Solution Recalled for Subpotency
FDA (Drugs) · 2023-03-01
- HighThyroid Drug TIROSINT Recalled Due to Subpotent Formulation
FDA (Drugs) · 2023-03-01
- HighLevothyroxine oral solution TIROSINT recalled nationwide for subpotency
FDA (Drugs) · 2023-03-01
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateMedline Ophthalmic Pack with Lidocaine Injection Kits Recalled
FDA (Devices) · 2026-07-08
- SevereAccucaine Lidocaine Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Sterile Solution Lacks Assurance of Sterility
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Antiseptic Applicators recalled for lack of sterility assurance
FDA (Drugs) · 2026-07-08